Obesity biotech Corxel is moving toward US public markets through a SPAC deal following new financing disclosures. Corxel’s oral obesity candidates—described as small-molecule and designed to compete in the oral GLP-1 category—are positioned to advance toward Phase 3, with the company expecting the transaction to close in the first half of 2027. The company’s announcement highlights a strategic push into the rapidly crowded oral incretin market, where differentiation increasingly centers on tolerability, dosing convenience, and early evidence of metabolic outcomes. Corxel is framing the move as a way to fund the next clinical stage as competitors progress. For investors and development teams, the SPAC path underscores how capital formation is continuing to re-open for metabolic disease platforms with near-term registrational intent.